AR052233A1 - Formulacion liofilizada, estabilizada, para derivados de la cefalosporina - Google Patents

Formulacion liofilizada, estabilizada, para derivados de la cefalosporina

Info

Publication number
AR052233A1
AR052233A1 ARP050104706A ARP050104706A AR052233A1 AR 052233 A1 AR052233 A1 AR 052233A1 AR P050104706 A ARP050104706 A AR P050104706A AR P050104706 A ARP050104706 A AR P050104706A AR 052233 A1 AR052233 A1 AR 052233A1
Authority
AR
Argentina
Prior art keywords
formulation
liophilized
stabilized
cephalosporine derivatives
derivatives
Prior art date
Application number
ARP050104706A
Other languages
English (en)
Original Assignee
Basilea Pharmaceutica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica Ag filed Critical Basilea Pharmaceutica Ag
Publication of AR052233A1 publication Critical patent/AR052233A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formulacion liofilizada para derivados de cefalosporina, que tiene una estabilidad incrementada, a una solucion para la obtencion de dicha formulacion, a un procedimiento para la preparacion de tal tipo de formulacion, así como también al uso de ciertos compuestos para estabilizar derivados de cefalosporina, en formulaciones liofilizadas. Los compuestos que se utilizan de una forma preferente, como estabilizadores en concordancia con la presente son, manitol, trealosa y polivinilpirrolidona (PVP).
ARP050104706A 2004-11-10 2005-11-09 Formulacion liofilizada, estabilizada, para derivados de la cefalosporina AR052233A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04405690A EP1656930A1 (en) 2004-11-10 2004-11-10 Stabilized freeze-dried formulation for cephalosporin derivatives

Publications (1)

Publication Number Publication Date
AR052233A1 true AR052233A1 (es) 2007-03-07

Family

ID=34932353

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104706A AR052233A1 (es) 2004-11-10 2005-11-09 Formulacion liofilizada, estabilizada, para derivados de la cefalosporina

Country Status (24)

Country Link
US (2) US20080032962A1 (es)
EP (3) EP1656930A1 (es)
JP (1) JP2008519775A (es)
KR (1) KR20070084150A (es)
CN (1) CN101056623B (es)
AR (1) AR052233A1 (es)
AT (1) ATE468844T1 (es)
AU (1) AU2005304252B2 (es)
BR (1) BRPI0517305A (es)
CA (1) CA2585296A1 (es)
CY (1) CY1110731T1 (es)
DE (1) DE602005021530D1 (es)
DK (1) DK1809253T3 (es)
ES (1) ES2342833T3 (es)
HR (1) HRP20100364T1 (es)
MX (1) MX2007005677A (es)
MY (1) MY142648A (es)
PL (1) PL1809253T3 (es)
PT (1) PT1809253E (es)
RS (1) RS51380B (es)
SI (1) SI1809253T1 (es)
TW (1) TW200630118A (es)
WO (1) WO2006050631A1 (es)
ZA (1) ZA200703760B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080103121A1 (en) * 2006-10-30 2008-05-01 Gole Dilip J Cephalosporin derivative formulation
TWI488657B (zh) * 2006-12-07 2015-06-21 Daiichi Sankyo Co Ltd 貯藏安定性經改善之醫藥組成物及改善醫藥組成物之貯藏安定性的方法
BRPI0719393B8 (pt) 2006-12-07 2021-05-25 Daiichi Sankyo Co Ltd composição farmacêutica
AU2009222020A1 (en) * 2008-03-04 2009-09-11 Elan Pharma International Limited Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens
EP2106788A1 (en) * 2008-04-04 2009-10-07 Ipsen Pharma Liquid and freeze dried formulations
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
US20130089638A1 (en) 2011-10-11 2013-04-11 Mead Johnson Nutrition Company Compositions Comprising Maltotriose And Methods Of Using Same To Inhibit Damage Caused By Dehydration Processes
CN102727451B (zh) * 2012-07-03 2013-07-03 哈药集团制药总厂 一种含有头孢美唑钠的药物组合物
CN102716075B (zh) * 2012-07-03 2013-08-21 哈药集团制药总厂 一种含有头孢唑肟钠的药物组合物
CN103271877A (zh) * 2012-12-18 2013-09-04 张宏民 一种头孢西丁钠注射剂及其制备方法
DK2968446T3 (en) 2013-03-13 2017-08-28 Theravance Biopharma Antibiotics Ip Llc HCL-Salts of an antibiotic compound
CN110507619B (zh) * 2019-08-19 2021-12-03 湖北美林药业有限公司 注射用头孢哌酮钠及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2690009B2 (ja) * 1986-07-10 1997-12-10 エーザイ 株式会社 セフアロスポリン注射剤
DE3801179A1 (de) * 1988-01-18 1989-07-27 Hoechst Ag Stabilisierung von cephalosporinderivaten durch trocknung mit einem stabilisator sowie stabile zubereitungsformen mit cephalosporinderivaten
ATE97810T1 (de) * 1989-09-30 1993-12-15 Eisai Co Ltd Injizierbare cephalosporinpraeparate und ihre anwendung.
JPH0459730A (ja) * 1990-06-26 1992-02-26 Dai Ichi Seiyaku Co Ltd セフェム系抗生物質含有凍結乾燥製剤
ID27686A (id) * 1998-06-15 2001-04-19 Hoffmann La Roche Turunan 3-(2-okso-[1,3]bipirolidinil-3-ildenametil)-sefem
US7378408B2 (en) * 2001-11-30 2008-05-27 Pfizer Inc. Methods of treatment and formulations of cephalosporin
WO2004000323A1 (ja) * 2002-06-21 2003-12-31 Shionogi & Co., Ltd. セフェム化合物の注射用医薬組成物

Also Published As

Publication number Publication date
MY142648A (en) 2010-12-15
DK1809253T3 (da) 2010-07-12
ZA200703760B (en) 2008-06-25
CY1110731T1 (el) 2015-06-10
US20080032962A1 (en) 2008-02-07
AU2005304252A1 (en) 2006-05-18
WO2006050631A1 (en) 2006-05-18
EP2210592A2 (en) 2010-07-28
PL1809253T3 (pl) 2010-10-29
MX2007005677A (es) 2007-07-20
JP2008519775A (ja) 2008-06-12
EP1809253A1 (en) 2007-07-25
CN101056623B (zh) 2011-04-06
RS51380B (en) 2011-02-28
ES2342833T3 (es) 2010-07-15
DE602005021530D1 (de) 2010-07-08
EP2210592A3 (en) 2011-12-14
EP1809253B1 (en) 2010-05-26
SI1809253T1 (sl) 2010-09-30
CA2585296A1 (en) 2006-05-18
TW200630118A (en) 2006-09-01
PT1809253E (pt) 2010-09-03
ATE468844T1 (de) 2010-06-15
KR20070084150A (ko) 2007-08-24
AU2005304252B2 (en) 2009-07-16
EP1656930A1 (en) 2006-05-17
CN101056623A (zh) 2007-10-17
BRPI0517305A (pt) 2008-10-07
HRP20100364T1 (hr) 2010-07-31
US20100160278A1 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
AR052233A1 (es) Formulacion liofilizada, estabilizada, para derivados de la cefalosporina
CL2008002687A1 (es) Uso de una combinacion farmaceutica de un compuesto derivado de tieno[3,2-d]pirimidina con un agente quimioterapeutico en el tratamiento de un trastorno hiperproliferativo; kit farmaceutico.
CL2012000707A1 (es) Compuestos derivados de [5-(pirrolo[1,2-c][1.2.3]triazin-7-il)tetrahidrofuran-2-il]metanol; composición farmacéutica; y su uso para el tratamiento de la hepatitis c.
UY29705A1 (es) " inhibidores macrocíclicos del virus de la hepatitis c"
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
PA8842201A1 (es) Inhibidores macrocíclicos de serina proteasas de hepatitis c
PA8785401A1 (es) Derivados de bencimidazol
SV2009003432A (es) Compuestos activos biciclicos 1,3-diones de herbicidas
CL2008001951A1 (es) Compuestos derivados de imidazo[1,2-a]pirimidin-2-ilmetil sustituidos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el trastorno del sueno, depresion, ansiedad, trastorno relacionado con el abuso de sustancias, entre otras.
PA8551001A1 (es) Nuevos compuestos
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
CY1115863T1 (el) Ενωσεις τριαζολοπyριδινης
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CO2019004190A2 (es) Formulaciones liposomales para uso en el tratamiento del cáncer
AR063942A1 (es) Compuestos de oximilo aciclico inhibidores de proteasa del virus de hepatitis c
ECSP15035530A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
ECSP12012338A (es) Triazolopiridinas sustituidas
PA8623101A1 (es) Compuestos farmaceuticamente activos
TN2011000261A1 (en) Octreotide depot formulation with constantly high exposure levels
GT200300227A (es) Formulaciones de liberacion prolongada en forma de suspension
GT200900287A (es) Extrudidos con enmascaramiento del sabor mejorado
SV2006002089A (es) Nuevos imidazoles ref. docket 18699 (pc26195a)
GT200600039A (es) Tiazolidinonas, su preparacion y su uso como medicamento
CL2009001089A1 (es) Compuestos derivados de indolo[2,1-a][2]benzacepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal